Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome

Aim. In patients with acute coronary syndrome (ACS), to detect pre-activated (primed) phagocytes in peripheral blood and to evaluate the effects of trimetazidine MB, when added to standard therapy, on reactive oxygen species (ROS) production Material and methods. In 113 hospitalised ACS patients 86 with myocardial infraction (MI) and 27 with unstable angina (UA) - the dynamics of blood leukocytes and ROS (baseline activity and PMA (phorbol-12-myristate-13-acetate) stimulated activity) was assessed by lumen-dependent chemiluminescence method In 60 participants, trimetazidine MB (70 mg/d) abets on ROS production were investigated Results. At hospital admission, blood leukocyte levels, basal and PMA-stimulated ROS production were significantly higher in AMI patients (especially in those who subsequently died) than in UA participants Trimetazidine MB therapy facilitated more rapid and manifested leukocyte count reduction, compared to the standard therapy alone the respective reductions at Days 3-5, 7-10, and 15-21 were -20 vs -14%, -37 vs -30%, and -47 vs -32% In the trimetazidine MB group, the basal and PMA-stimulated ROS production did not change significantly, while in the standard therapy group, the ROS production increased from Day 3 to Day 15 Conclusion. Adding trimetazidine MB to standard therapy of ACS patients significantly reduced the peripheral blood leukocyte count at Days 15-21, without leukocyte activation in the sub-acute phase of myocardial ischemia